Journal
FRONTIERS IN IMMUNOLOGY
Volume 12, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.705974
Keywords
peptide vaccines; HLA peptides; chronic lymphocytic leukemia; mass spectrometry; peptide warehouse; immunopeptidomics; immunotherapy
Categories
Funding
- Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) [WA 4608/1-2]
- Deutsche Forschungsgemeinschaft [EXC2180-390900677]
- German Cancer Consortium (DKTK)
- Wilhelm Sander Stiftung [2016.177.2]
- Jose Carreras Leukamie-Stiftung [DJCLS 05 R/2017]
- Fortune Program of the University of Tubingen [2451-0-0, 2581-0-0]
Ask authors/readers for more resources
The study developed an immunopeptidome-guided workflow for designing tumor-associated off-the-shelf peptide warehouses for broadly applicable personalized therapeutics, which can be easily transferred to other tumor entities and serve as the foundation for broad personalized T cell-based immunotherapy approaches.
Antigen-specific immunotherapies, in particular peptide vaccines, depend on the recognition of naturally presented antigens derived from mutated and unmutated gene products on human leukocyte antigens, and represent a promising low-side-effect concept for cancer treatment. So far, the broad application of peptide vaccines in cancer patients is hampered by challenges of time- and cost-intensive personalized vaccine design, and the lack of neoepitopes from tumor-specific mutations, especially in low-mutational burden malignancies. In this study, we developed an immunopeptidome-guided workflow for the design of tumor-associated off-the-shelf peptide warehouses for broadly applicable personalized therapeutics. Comparative mass spectrometry-based immunopeptidome analyses of primary chronic lymphocytic leukemia (CLL) samples, as representative example of low-mutational burden tumor entities, and a dataset of benign tissue samples enabled the identification of high-frequent non-mutated CLL-associated antigens. These antigens were further shown to be recognized by pre-existing and de novo induced T cells in CLL patients and healthy volunteers, and were evaluated as pre-manufactured warehouse for the construction of personalized multi-peptide vaccines in a first clinical trial for CLL (NCT04688385). This workflow for the design of peptide warehouses is easily transferable to other tumor entities and can provide the foundation for the development of broad personalized T cell-based immunotherapy approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available